The BioProcess International Conference and Exhibition has earned its reputation as the leading bioprocessing industry event. Over 2000 attendees and suppliers use the event to network, learn, and catch-up with colleagues while looking for tangible applications of the latest technical, scientific and strategic innovations needed to accelerate promising biologics towards commercial success.
BioProcess International, sister publication and official publication of the event, is pleased to be the exclusive provider of pre-event podcast series created to provide confirmed and prospective attendees with a preview of what you will experience and learn at the 2018 BioProcess International Conference & Exhibition.
We have gathered a VIP group of speakers who sat down (virtually!) with Dan Stanton, editor of BioProcess Insider, to share their expert perspectives and commentary on the scientific and technological trends impacting Cell Culture & Upstream Processing; Recovery & Purification; Manufacturing Strategies; and Analytical & Quality; and Speed from Gene to Market.
Click here to listen to the following industry experts as they discuss their experiences and predictions, while previewing the event:
- Jie Xu, Merck
- Michael Butler, NIBRT
- Rushd Khalaf, Novartis
- Anna Senczuk, Shire
- Derek Willison-Parry, BioPhorum
- Jeff Johnson, Merck
- Sanchayita Ghose, BMS
- Chris Chumsae, Abbvie
- Balaji Viswanathan, Pfizer
- Regina Au, Biomarketing Insight
- Gene Lee, EMD Serono
To get you started, we are pleased to highlight Dan’s conversation with Günter Jagschies focusing on the latest trends impacting development, design, and implementation of manufacturing processes.
Günter Jagschies, Senior Director, Strategic Customer Relations, GE Healthcare, Germany
Full Session: 8:20 am, Weds. Sep. 5, 2018
A veteran attendee and speaker at BPI, in this podcast Jagschies gives us a brief overview of how biopharma companies have matured and begun focusing on manufacturing technologies and efficiencies, “turning their focus onto normal management mechanisms and not just on the naked success of their molecules.” However, cost-savings will always be trumped by time-to-clinic, which remains a crucial component in the minds of biopharmaceutical developers, he says.
But whether speed, efficiency or cost, Jagschies looks to end-user vendor relationships to drive innovations going forwards.